Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy.

He J, Shen D, Chung DU, Saxton RE, Whitelegge JP, Faull KF, Chang HR.

Int J Oncol. 2009 Oct;35(4):683-92.

PMID:
19724903
2.

Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers.

Whelan SA, Lu M, He J, Yan W, Saxton RE, Faull KF, Whitelegge JP, Chang HR.

J Proteome Res. 2009 Aug;8(8):4151-60. doi: 10.1021/pr900322g.

3.

The MUC1 oncoprotein as a functional target: immunotoxin binding to alpha/beta junction mediates cell killing.

Rubinstein DB, Karmely M, Pichinuk E, Ziv R, Benhar I, Feng N, Smorodinsky NI, Wreschner DH.

Int J Cancer. 2009 Jan 1;124(1):46-54. doi: 10.1002/ijc.23910.

4.

A proteomics study on human breast cancer cell lines by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry.

Imai K, Ichibangase T, Saitoh R, Hoshikawa Y.

Biomed Chromatogr. 2008 Nov;22(11):1304-14. doi: 10.1002/bmc.1102.

PMID:
18821527
5.

Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma.

Liu YF, Xiao ZQ, Li MX, Li MY, Zhang PF, Li C, Li F, Chen YH, Yi H, Yao HX, Chen ZC.

J Pathol. 2009 Jan;217(1):54-64. doi: 10.1002/path.2429.

PMID:
18798225
6.
7.

Review. EGFR mutations in non-small cell lung cancer--clinical implications.

Charpidou A, Blatza D, Anagnostou V, Syrigos KN.

In Vivo. 2008 Jul-Aug;22(4):529-36. Review. Erratum in: In Vivo. 2008 Nov-Dec;22(6):886. Anagnostou, Elsa [corrected to Anagnostou, Valsamo].

8.

High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.

Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL.

J Cell Mol Med. 2009 Aug;13(8B):2236-52. doi: 10.1111/j.1582-4934.2008.00455.x.

9.

Heat shock proteins as novel therapeutic targets in cancer.

Soo ET, Yip GW, Lwin ZM, Kumar SD, Bay BH.

In Vivo. 2008 May-Jun;22(3):311-5. Review.

10.

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.

Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC.

J Natl Cancer Inst. 2008 May 7;100(9):672-9. doi: 10.1093/jnci/djn123.

11.

Transformation, translation and TRAIL: an unexpected intersection.

White-Gilbertson S, Rubinchik S, Voelkel-Johnson C.

Cytokine Growth Factor Rev. 2008 Apr;19(2):167-72. doi: 10.1016/j.cytogfr.2008.01.007. Review.

12.

Cancer statistics, 2008.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.

CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010.

13.

Triple negative breast cancer: current understanding of biology and treatment options.

Kang SP, Martel M, Harris LN.

Curr Opin Obstet Gynecol. 2008 Feb;20(1):40-6. doi: 10.1097/GCO.0b013e3282f40de9. Review.

PMID:
18197004
14.

[The cancer stem cell: the breast cancer driver].

Ginestier C, Korkaya H, Dontu G, Birnbaum D, Wicha MS, Charafe-Jauffret E.

Med Sci (Paris). 2007 Dec;23(12):1133-9. Review. French.

15.

Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.

Diaz LK, Cryns VL, Symmans WF, Sneige N.

Adv Anat Pathol. 2007 Nov;14(6):419-30. Review.

PMID:
18049131
16.

The E-cadherin gene polymorphism 160C->A and cancer risk: A HuGE review and meta-analysis of 26 case-control studies.

Wang GY, Lu CQ, Zhang RM, Hu XH, Luo ZW.

Am J Epidemiol. 2008 Jan 1;167(1):7-14. Review.

17.

Proteomics of integral membrane proteins--theory and application.

Speers AE, Wu CC.

Chem Rev. 2007 Aug;107(8):3687-714. Review. No abstract available.

PMID:
17683161
19.
20.

Triple-negative breast cancer: therapeutic options.

Cleator S, Heller W, Coombes RC.

Lancet Oncol. 2007 Mar;8(3):235-44. Review.

PMID:
17329194
Items per page

Supplemental Content

Support Center